石杉碱甲治疗改善脑器质性疾病患者的记忆和认知功能

背景石杉碱甲是从千层塔草药中提炼的胆碱酯酶抑制剂,具有促进记忆再现和增强记忆保持的作用.目的应用石杉碱甲治疗血管性痴呆和阿尔茨海默病患者,探讨其对记忆和认知功能的改善作用.设计病例分析.单位南京医科大学附属脑科医院老年精神科.对象选择2000-03/2002-03南京医科大学附属脑科医院老年精神科患者64例.男30例,女34例;其中血管性痴呆41例(血管性痴呆组),阿尔茨海默病23例(阿尔茨海默病组).方法两组患者均服用石杉碱甲片剂,每日总剂量为200 μg,2次/d共治疗8周.治疗前后采用记忆商值、简易智能状态量表评分评定疗效.疗效评定标准①显效治疗后记忆商值、简易智能状态量表评分比治疗前提高25%以上,以及临床症状明显改善.②有效记忆商值、简易智能状态量表评分分别提高15%以上,以及临床症状有改善.③其他视为无效病例.主要观察指标①两组患者治疗8周后疗效.②两组患者治疗前后记忆商值、简易智能状态量表、日常生活活动能力评分.结果64例患者全部进入结果分析.①两组患者治疗8周后疗效血管性痴呆组总有效率为71%,明显高于阿尔茨海默病组(48%)(P＜0.01).其中痴呆程度越重,疗效越差.②记忆商值、简易智能状态量表、日常生活活动能力评分两组患者治疗后记忆商值、简易智能状态量表评分均明显高于治疗前(P＜0.05～0.01).而日常生活活动能力评分无明显改善(P＞0.05).结论石杉碱甲能有效改善脑器质性疾病患者记忆和认知能力,具有较好的疗效.

Huperzine A for improving the memory and cognitive function in patients with organic brain diseases

BACKGROUND: Huperzine A, a cholinesterase inhibitor extracted from qiancengta herb, can promote the recovery of memory and strengthen memory retention.OBJECTIVE: To probe into the ameliorating effect of huperzine A on memory and cognitive function in patients with vascular dementia (VD) and Alzheimer's disease (AD).DESIGN: Case analysis.SETTING: Department of Geriatric Psychiatry, Brain Hospital of Nanjing Medical University.PARTICIPANTS:Totally 64 patients, 30 males and 34 females treated in the Department of Geriatric Psychiatry, Brain Hospital of Nanjing Medical University, between March 2000 and March 2002 were recruited. Among them, there were 41 cases of VD (VD group) and 23 cases of AD (AD group).METHODS: Patients in the two groups all took huperzine A tablets orally, at a total dose of 200 μg a day, twice a day for 8 weeks. Memory quotient (MQ) value and Mini Mental Status Examination (MMSE) score were used before and after treatment to evaluate the curative effects. Evaluate were enhanced by 25% compared to those before treatment and the clinical score were enhanced by 15% separately, and the clinical symptoms were activity ability score in patients before and after treatment.fect on patients in the two groups 8 weeks after treatment: The total effective rate in VD group was 71%, which was significantly higher than that in AD group (48%) (P ＜ 0.01). The severer dementia was, the less curative and MMSE score of patients in the two groups were significantly higher after treatment than before treatment (P ＜ 0.05-0.01). However, score of daily activity ability did not obviously differ (P ＞ 0.05).CONCLUSION: Huperzine A can effectively improve memory and cognitive function in patients with organic brain diseases and has good curative effects.